ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
B-cell Childhood Acute Lymphoblastic Leukemia
Children's Oncology Groupprotein_peptidePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the B-cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
Calcium folinate pentahydrate Children's Oncology Group | Phase 3 | BBB |
ASPARAGINASE National Cancer Institute (NCI) | Phase 3 | BB |
Cediranib National Cancer Institute (NCI) | Phase 3 | BB |
ETOPOSIDE St. Jude Children's Research Hospital | Phase 3 | BB |
View all 29 →
Same molecule, other indications
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →